Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet-latelet-.

R H Eckel, E B Crowell, B E Waterhouse

    Archives of Internal Medicine
    |June 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Platelet-inhibiting drugs, including aspirin, dipyridamole, and sulfinpyrazone, showed promise in treating thrombotic thrombocytopenic purpura (TTP). These medications, used with or without splenectomy and prednisone, helped two patients achieve remission.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Response by Ward et al to Letter Regarding Article, "Statin Toxicity: Mechanistic Insights and Clinical Implications".

    Circulation research·2019
    Same author

    Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.

    Diabetes, obesity & metabolism·2016
    Same author

    Dietary triglycerides act on mesolimbic structures to regulate the rewarding and motivational aspects of feeding.

    Molecular psychiatry·2014
    Same author

    Obesity development in caspase-1-deficient mice.

    International journal of obesity (2005)·2013
    Same author

    Adults with type 1 diabetes eat a high-fat atherogenic diet that is associated with coronary artery calcium.

    Diabetologia·2009
    Same author

    Obesity research in the next decade.

    International journal of obesity (2005)·2009

    Area of Science:

    • Hematology
    • Internal Medicine
    • Pharmacology

    Background:

    • Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
    • Standard treatments for TTP include plasma exchange, corticosteroids, and splenectomy, but remission can be challenging to achieve or maintain.

    Observation:

    • Two TTP patients were treated with platelet-inhibiting drugs.
    • Patient 1, post-splenectomy, received aspirin, dipyridamole, and sulfinpyrazone after high-dose corticosteroids failed. Remission was achieved and sustained upon adjusting dipyridamole dosage.
    • Patient 2, without splenectomy, received the same platelet-inhibiting drugs plus prednisone, achieving a prompt and sustained remission.

    Findings:

    • Platelet-inhibiting drugs, in combination with other therapies, appear to induce remission in TTP.

    Related Experiment Videos

  • Dipyridamole dosage adjustment was critical for maintaining remission in one patient.
  • Peripheral blood smear abnormalities resolved slower than clinical symptoms.

    • Implications:

    • Platelet-inhibiting drugs represent a potential therapeutic option for TTP, particularly in refractory cases.
    • Further research is warranted to elucidate the precise mechanisms and optimal use of these agents in TTP management.
    • These findings may guide treatment strategies for TTP, potentially improving patient outcomes.